| Dr Sean Aaron Deitch, MD | |
|
9888 Genesee Ave, La Jolla, CA 92037-1205 | |
| (858) 626-6150 | |
| (858) 626-7117 |
| Full Name | Dr Sean Aaron Deitch |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 26 Years |
| Location | 9888 Genesee Ave, La Jolla, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942230297 | NPI | - | NPPES |
| 00A693670 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A69367 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Scripps Memorial Hospital La Jolla | La jolla, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| La Jolla Observation Medicine | 2365727492 | 23 |
News Archive
Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis.
The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences. Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of researchers, led by George Kunos, at the National Institutes of Health, Bethesda, and Alexandros Makriyannis, at Northeastern University, Boston, have developed a drug that has the same positive effects in mice on levels of glucose and fats in the blood as rimonabant but none of the neurological side effects.
According to the Centers for Disease Control, during 2000-2004, "An estimated 443,000 persons in the United States died prematurely each year from smoking or exposure to secondhand smoke.
AliveCor, the developer of a breakthrough mobile electrocardiogram (ECG) recorder, today announced results from a study that demonstrated the accuracy of the company's iPhone-based device, by comparing its Lead I to Lead I from a conventional 12-lead ECG. The study found that the iPhone-based event recorder is an accurate clinical tool for ECG assessment and could prove to be a new tool for allowing immediate recording and analysis of an ECG rhythm.
A cancer cell breaks away from a primary tumor and settles in a new location, where it once again divides.
› Verified 7 days ago
| Entity Name | La Jolla Emergency Specialists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710315353 PECOS PAC ID: 1153552039 Enrollment ID: O20140317001669 |
News Archive
Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis.
The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences. Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of researchers, led by George Kunos, at the National Institutes of Health, Bethesda, and Alexandros Makriyannis, at Northeastern University, Boston, have developed a drug that has the same positive effects in mice on levels of glucose and fats in the blood as rimonabant but none of the neurological side effects.
According to the Centers for Disease Control, during 2000-2004, "An estimated 443,000 persons in the United States died prematurely each year from smoking or exposure to secondhand smoke.
AliveCor, the developer of a breakthrough mobile electrocardiogram (ECG) recorder, today announced results from a study that demonstrated the accuracy of the company's iPhone-based device, by comparing its Lead I to Lead I from a conventional 12-lead ECG. The study found that the iPhone-based event recorder is an accurate clinical tool for ECG assessment and could prove to be a new tool for allowing immediate recording and analysis of an ECG rhythm.
A cancer cell breaks away from a primary tumor and settles in a new location, where it once again divides.
› Verified 7 days ago
| Entity Name | La Jolla Observation Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780122986 PECOS PAC ID: 2365727492 Enrollment ID: O20170331001702 |
News Archive
Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis.
The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences. Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of researchers, led by George Kunos, at the National Institutes of Health, Bethesda, and Alexandros Makriyannis, at Northeastern University, Boston, have developed a drug that has the same positive effects in mice on levels of glucose and fats in the blood as rimonabant but none of the neurological side effects.
According to the Centers for Disease Control, during 2000-2004, "An estimated 443,000 persons in the United States died prematurely each year from smoking or exposure to secondhand smoke.
AliveCor, the developer of a breakthrough mobile electrocardiogram (ECG) recorder, today announced results from a study that demonstrated the accuracy of the company's iPhone-based device, by comparing its Lead I to Lead I from a conventional 12-lead ECG. The study found that the iPhone-based event recorder is an accurate clinical tool for ECG assessment and could prove to be a new tool for allowing immediate recording and analysis of an ECG rhythm.
A cancer cell breaks away from a primary tumor and settles in a new location, where it once again divides.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sean Aaron Deitch, MD Po Box 661987, Arcadia, CA 91066-1987 Ph: (626) 447-0296 | Dr Sean Aaron Deitch, MD 9888 Genesee Ave, La Jolla, CA 92037-1205 Ph: (858) 626-6150 |
News Archive
Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis.
The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences. Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of researchers, led by George Kunos, at the National Institutes of Health, Bethesda, and Alexandros Makriyannis, at Northeastern University, Boston, have developed a drug that has the same positive effects in mice on levels of glucose and fats in the blood as rimonabant but none of the neurological side effects.
According to the Centers for Disease Control, during 2000-2004, "An estimated 443,000 persons in the United States died prematurely each year from smoking or exposure to secondhand smoke.
AliveCor, the developer of a breakthrough mobile electrocardiogram (ECG) recorder, today announced results from a study that demonstrated the accuracy of the company's iPhone-based device, by comparing its Lead I to Lead I from a conventional 12-lead ECG. The study found that the iPhone-based event recorder is an accurate clinical tool for ECG assessment and could prove to be a new tool for allowing immediate recording and analysis of an ECG rhythm.
A cancer cell breaks away from a primary tumor and settles in a new location, where it once again divides.
› Verified 7 days ago
Mrs. Susan Elizabeth Mckim, PA-C Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-8646 Fax: 858-554-6271 | |
Dr. Monte Tim Mellon, M.D. M.B.A. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9888 Genesee Ave, La Jolla, CA 92037 Phone: 858-626-6150 Fax: 858-626-7117 | |
Richard M Obler, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 354 Ricardo Pl, La Jolla, CA 92037 Phone: 858-922-1073 | |
Ian R Grover, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9300 Campus Point Drive, La Jolla, CA 92037 Phone: 858-657-7000 | |
Ian Reilly, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9888 Genesee Ave, La Jolla, CA 92037 Phone: 858-354-6049 | |
George R Baehr, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 10710 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-8638 | |
Sean X Neath, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9300 Campus Point Dr, La Jolla, CA 92037 Phone: 858-657-7000 |